Vascular Biogenics Surges for Third Day on Cancer Drug ProspectBy
Company to present data on VB-111 drug on Sept. 27 in Vienna
Chardan rated stock a buy on promise of gene therapy drug
Vascular Biogenics Ltd., the Israeli biotechnology company that is developing cancer treatments, rallied for a third day on bets it will show promising results from clinical drug trials at a medical conference in Europe this weekend.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.